Associated Genetic Biomarkers
Fli-1 proto-oncogene, ETS transcription factor (FLI1) is a gene that encodes a protein that functions as an ETS DNA-binding domain containing transcription factor. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as intestinal cancer, parathyroid cancer, and skin cancer.
FLI1 is altered in 0.88% of all cancers with sarcoma, colorectal adenocarcinoma, non-small cell lung carcinoma, prostate cancer, and head and neck cancer having the greatest prevalence of alterations .
The most common alterations in FLI1 are FLI1 G449D (0.00%), FLI1 Q370K (0.00%), FLI1 R68Q (0.00%), FLI1 T249M (0.00%), and FLI1 X277_splice (0.00%) .
FLI1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains FLI1 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with FLI1 status in the inclusion eligibility criteria most commonly target Ewing sarcoma .
The most frequent alteration to serve as an inclusion eligibility criterion is EWSR1-FLI1 Fusion .
Significance of FLI1 in Diseases
Ewing Sarcoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.